Palantir Stock Skyrockets on Massive UK AI-Defense Pact – Could PLTR Eclipse Oracle by 2030?
1 November 2025
9 mins read

Palantir (PLTR) Stock Skyrockets to Record High as AI Boom Ignites 300% Rally – Could $200 Be Just the Start?

  • Price (Nov 1, 2025): ~$200.47 per share (closed Oct. 31) [1], up roughly +300% YTD. PLTR’s market capitalization is about $425–438 billion [2] [3].
  • Recent Stock Rally: PLTR hit an all-time intraday high near ~$190 on Oct. 27, 2025 [4], briefly touching $200+ as investors piled into AI and government-contract plays. Shares have more than tripled in 2025 on a “steady drumbeat” of big contract wins and a broader tech/AI rally [5] [6].
  • Major Deals & Partnerships: Palantir in late 2025 has racked up headline partnerships. Notable wins include the U.S. Army’s consolidation of dozens of contracts into a 10-year, up-to-$10 billion enterprise deal [7]; a Lumen Technologies collaboration on enterprise AI networking (~$200M deal) [8]; a strategic tie-up with Boeing Defense to deploy Palantir AI tools [9]; and a new NVIDIA integration announced Oct. 28, 2025 to combine Palantir’s Ontology platform with NVIDIA GPUs for AI logistics and decision-making [10] [11]. In Sept 2025 the UK government announced Palantir would invest up to £1.5 billion in a UK defense-innovation hub [12]. These deals span defense, telecom, aerospace, and tech sectors, underpinning strong demand for Palantir’s AI/data analytics platforms.
  • Financials (Q2 2025): In Q2 (ended June 2025) Palantir reported $1.004 billion in revenue (up 48% YoY) [13]. Government revenue was $426M (+53%) and U.S. commercial $306M (+93%) [14]. Non-GAAP net income was ~$327M. Operating income was $464M (46% of revenue) and free cash flow $569M (57% margin) [15]. Management raised full-year 2025 revenue guidance to roughly $4.15 billion [16]. These are far stronger results than prior years, driven by robust federal contracts and accelerating commercial sales (healthcare, telecom, energy, etc.).
  • Analyst Sentiment & Targets: Wall Street is split. Bulls point to Palantir’s AI leverage and contracts, with Wedbush’s Dan Ives calling it “one of the best AI stocks” and forecasting a $1 trillion valuation by ~2028 [17]. Piper Sandler recently lifted its 12-month target to $201. Bank of America raised its target to $215 [18]. Bears argue the valuation is stretched: one short-seller called it “absurd,” suggesting fair value near $65–$70 [19]. The median 12-month price target across analysts is in the $155–160 range [20] [21] (below today’s price). MarketBeat reports ~5 Buys, 15 Holds, 2 Sells (consensus Hold) with an average target ~$141 [22]. TipRanks (19 analysts) shows a mean target ~$157 (range ~$45–$215) [23].
  • Upcoming Catalysts: Palantir is set to report Q3 2025 earnings on Nov. 3, 2025. Street forecasts call for revenue in the ~$1.08–1.10B range (≈+50% YoY) and continued profitability. Investors will watch for any shifts in contract mix, guidance tweaks, and further AI product launches (e.g. generative AI features in Palantir’s AIP platform). Separately, ongoing “stock split” chatter has swirled – some brokers polled investors on a possible split as PLTR’s share price climbed – but Palantir has given no indication of an imminent split [24] [25].

Recent News & Market Drivers

Palantir’s stock surge in late Oct. 2025 was fueled by fresh news flow and a broad tech rally. Key developments in the past few days include:

  • Army’s $10B Deal (Aug 2025): The U.S. Army announced an “enterprise agreement” consolidating ~75 legacy contracts into one streamlined deal, giving it volume-based discounts and the option to buy up to $10 billion of Palantir software and services over 10 years [26]. This is the Pentagon’s largest data/AI contract and underscores Palantir’s role in U.S. defense. (Army CIO Leo Garciga called it “a pivotal step in modernizing our capabilities” [27].)
  • Lumen Partnership (Oct 27, 2025): Palantir announced a multi-year collaboration with telecom provider Lumen Technologies to marry Palantir’s AI Foundry platform with Lumen’s fiber and networking infrastructure. The deal is described as a “very large deal, and we’re very serious about it” by Palantir CEO Alex Karp [28]. It essentially creates a high-speed data pipeline (“the pipes”) for Palantir’s AI platforms, enabling real-time analytics for enterprise and defense customers [29] [30].
  • NVIDIA Alliance (Oct 28, 2025): NVIDIA and Palantir unveiled an integrated “operational AI” stack at a Washington conference [31] [32]. Palantir’s Ontology (the core of its AI Platform/AIP) will now include NVIDIA GPU-acceleration and open AI models. Jensen Huang (NVIDIA CEO) said this partnership puts “AI into action, turning enterprise data into decision intelligence” [33]. Karp echoed this, stating Palantir is “focused on deploying AI that delivers immediate, asymmetric value” and proud to fuse its system with NVIDIA’s “most advanced AI infrastructure” [34]. An early use-case is retailer Lowe’s, which will use Palantir+NVIDIA tech for dynamic supply-chain optimization [35].
  • Other Partnerships: In mid-Sep 2025, Boeing Defense and Space announced a deal to use Palantir’s AI platforms across its aircraft and satellite manufacturing lines [36]. In July, Palantir signed a $10B/year Army AI contract and a £1.5B UK defense pact [37] [38]. Palantir also has alliances with Snowflake and is reportedly in coalition talks with Anduril and others to bid on future Pentagon projects. Each announced contract has lifted PLTR shares.
  • Legal & Market Chatter: On Oct 30, Reuters reported Palantir sued two ex-senior engineers for founding a “copycat” AI startup (Percepta) and allegedly misusing its trade secrets [39] [40]. This highlights competition and IP concerns but has drawn little lasting market reaction. Meanwhile, industry chatter is strong: analysts say retail investors are excited by Palantir’s rally and are discussing a potential stock split to make shares more accessible [41] [42]. (Palantir has $6B cash on its balance sheet, yet management has not signaled any capital return or split plan [43].)

Financial Performance & Earnings

Palantir’s recent earnings have far outstripped past results. The Q2 2025 report (Aug 4 release) was a “blowout” [44]:

  • Revenue: $1.004 billion (48% ↑ YoY) [45]. This was the first time Palantir cleared $1B in a quarter.
  • Net Income: ~$327 million (non-GAAP) [46]. Palantir now generates significant operating profit and free cash flow (Q2 FCF $569M, 57% margin [47]).
  • Guidance: Management lifted FY2025 revenue guidance to about $4.142–4.150 billion [48]. This implies accelerating growth – Palantir is expected to exceed 40% full-year revenue growth, a rare feat for a software firm of its size.
  • Profitability: GAAP EPS was $0.13 (beat $0.12 exp.), with Q2 operating margin 46% [49]. Analysts note Palantir is now “in solid profitability” thanks to federal contracts and ramping commercial sales [50].

Investors will be watching Q3 results (due Nov 3, after market close). Consensus (from finance press previews) expects ~+50% YoY revenue to ~$1.08–1.10B with robust EPS growth. Any beat on Q3 could further fuel the rally; conversely a miss or any cautious guidance might trigger profit-taking given the sky-high valuation.

Market Sentiment & Outlook

Palantir’s stratospheric rise has created a buzz and some controversy. The stock trades at extremely rich multiples (about 100× forward sales and 200×+ forward earnings [51], with a trailing P/E near 630× [52]). Such levels rival dot-com bubble heights. Critics caution that any slip in growth or sentiment could cause a sharp selloff. One analyst notes that after Q2 results Palantir was trading at ~100× revenue [53]. By comparison, traditional defense firms trade in mid-teens P/S.

Bullish view: Proponents argue the valuation is justified by Palantir’s unique niche as an “AI arms dealer” and its secular growth runway. As Wedbush’s Dan Ives puts it, Palantir has become “one of the best AI stocks” and could one day hit the trillion-dollar club [54]. Bank of America highlighted that Palantir has thousands of high-margin deployment opportunities across industries. The large new contracts (Army, UK, Lumen) and commercial traction (Lowe’s, Snowflake, Airbus, etc.) suggest Palantir can sustain 30–50%+ growth for years.

Bearish view: Skeptics note the recent rally has perhaps overshot fundamentals. Short sellers and some value-oriented investors argue the stock is overhyped. One former research chief called the valuation “absurd” [55]. They point out concentration risk (much revenue still from a few government clients), aggressive insider selling (Karp and others sold stock earlier this year), and the possibility that AI enthusiasm could cool. MarketBear (a short-seller) argues fair value is closer to $65–$70, far below today’s levels [56].

Analyst consensus: As of Nov 2025, most Wall Street analysts have neutral-to-positive ratings. According to MarketBeat, out of ~22 surveyed analysts, 5 rate PLTR a Buy, 15 Hold, 2 Sell (avg. target ~$141) [57]. TipRanks’ consensus target is ~$157 [58]. In short, many see limited upside at current prices, but few are outright bearish. The range of targets is wide – from a few dozen dollars up to $215 – reflecting deep division on whether the surge is sustainable.

Long-term forecasts: Some AI strategists predict continued growth for Palantir over the next 3–5 years, assuming it maintains its government relationships and captures enterprise AI demand. For example, an AI-driven model (via ChatGPT) estimated Palantir could reach ~$189 per share by end-2025 under a bullish scenario [59]. However, such forecasts also stress the risks of valuation and volatility [60]. The coming year likely hinges on execution: further contract wins, expansion of the AI platform (AIP) into more industries, and how Palantir navigates rising competition (from cloud giants and specialized AI firms).

Business Highlights & Strategic Update

Palantir’s core businesses – government and commercial data analytics – are both accelerating:

  • Government & Defense: Historically Palantir’s bread-and-butter, the government segment is booming. The Army’s enterprise deal and UK investment deal show Palantir as a key U.S.-UK ally in AI/analytics. Palantir’s software is used by nearly every branch of the U.S. military and intelligence community. CEO Alex Karp often frames Palantir’s mission in geopolitical terms: “We’re in an [AI] arms race… either we’ll set the rules or adversaries will,” he told Fox Business [61]. This urgency (accentuated by competition with China and Russia) has translated into more large, long-term contracts. For instance, Karp emphasizes that if the U.S. does not build its own AI systems “our enemies might build it, and we will be buying everything from them” [62].
  • Commercial Growth: Palantir is aggressively expanding in the private sector. In 2025 it has landed dozens of commercial deals – from pharmaceuticals (e.g., Novartis) to logistics (Lowe’s) to manufacturing. Partnerships with cloud/data companies like Snowflake and NVIDIA are designed to broaden its reach in non-defense markets [63] [64]. Palantir’s Foundry and Apollo platforms are being infused with generative AI capabilities (embedding large language models) to appeal to enterprises grappling with big data. The new AI Platform (AIP) is central: it provides an “operational AI” layer on top of core analytics. This year Palantir announced multiple AI improvements (e.g. integration of Anthropic’s Claude 4.5 in AIP as of Oct 21, 2025) that make its tools more powerful for commercial clients.
  • Technology & Products: Palantir’s unique selling point is its “Ontology”-driven software engine that models real-world entities and their relationships. This allows customers to ask complex “what-if” questions of their combined data. With AI partners like NVIDIA, Palantir is bringing AI inference and optimization into this workflow. As Jensen Huang noted, the NVIDIA-Palantir stack enables “next-generation engine” for AI applications [65]. Palantir is also pushing heavily into cloud deployment and edge computing, aiming to be the back-end “brain” for AI across industries. Their message to investors: Palantir’s platform is an essential infrastructure for the AI era, from government battlefields to corporate boardrooms.
  • Growth Trajectory: The rapid Q2 growth (48%) shows momentum, but sustaining that pace will be challenging as the base scales. Analysts will watch the split between U.S. and international, gov vs. commercial. So far U.S. government remains the largest piece, but commercial grew faster. Palantir’s goal is to diversify its revenue mix – a successful pivot could justify its premium multiples. CEO Karp and other executives have repeatedly emphasized long-term contracts and a subscription-based model (unlike one-off projects), which could drive more predictable revenue. In recent earnings calls management has reiterated confidence, and the raised guidance implies they see ample backlog.

Conclusion

As of Nov 1, 2025, Palantir Technologies sits at a crossroads of hype and reality. On one hand, the stock’s phenomenal run (300% this year) reflects genuine enterprise momentum: surging revenues, major defense/AI contracts, and high-profile tech partnerships [66] [67]. On the other hand, the valuation has become stretched, drawing skepticism from value investors. The upcoming Q3 earnings (Nov. 3) and any new contract announcements will be critical tests. If Palantir again outperforms (and signals a growing commercial pipeline), bulls may feel vindicated. If growth falters or guidance disappoints, the stock could correct sharply.

Key takeaways: PLTR is now a headline AI/defense stock – widely regarded as a leader in combining big data and AI. The narrative (“AI arms race”, real-time operational intelligence, long-term government alliances) is compelling. Investors should watch the actual financials closely: the stock is pricing in near-perfect execution (a “bubble” in critics’ eyes), so patience and scrutiny are warranted. For those bullish on AI infrastructure, Palantir represents an ambitious bet on a company positioned at the intersection of data, AI and national security [68] [69].

Sources: Authoritative news reports and filings from Oct 30, 2025 and prior, including Reuters, Economic Times, TechStock² (TS2) analysis [70] [71], MarketBeat [72] [73], Fast Company [74] [75], NVIDIA press release [76], and Yahoo/Finbold market summaries [77], among others. These provide the latest stock data, earnings figures, and expert commentary on Palantir’s business.

WARNING: If You Hold NVIDIA Stock (NVDA)... GET READY

References

1. stockinvest.us, 2. www.marketbeat.com, 3. ts2.tech, 4. ts2.tech, 5. ts2.tech, 6. ts2.tech, 7. www.reuters.com, 8. www.ainvest.com, 9. www.reuters.com, 10. www.reuters.com, 11. nvidianews.nvidia.com, 12. mlq.ai, 13. economictimes.indiatimes.com, 14. economictimes.indiatimes.com, 15. economictimes.indiatimes.com, 16. economictimes.indiatimes.com, 17. ts2.tech, 18. www.marketbeat.com, 19. ts2.tech, 20. ts2.tech, 21. finbold.com, 22. www.marketbeat.com, 23. finbold.com, 24. www.fastcompany.com, 25. www.fastcompany.com, 26. www.reuters.com, 27. www.govconwire.com, 28. economictimes.indiatimes.com, 29. economictimes.indiatimes.com, 30. www.ainvest.com, 31. www.reuters.com, 32. nvidianews.nvidia.com, 33. nvidianews.nvidia.com, 34. nvidianews.nvidia.com, 35. nvidianews.nvidia.com, 36. www.reuters.com, 37. ts2.tech, 38. mlq.ai, 39. www.reuters.com, 40. www.reuters.com, 41. www.fastcompany.com, 42. www.fastcompany.com, 43. www.fastcompany.com, 44. ts2.tech, 45. economictimes.indiatimes.com, 46. economictimes.indiatimes.com, 47. economictimes.indiatimes.com, 48. economictimes.indiatimes.com, 49. investors.palantir.com, 50. ts2.tech, 51. www.ainvest.com, 52. www.fastcompany.com, 53. www.fastcompany.com, 54. ts2.tech, 55. ts2.tech, 56. ts2.tech, 57. www.marketbeat.com, 58. finbold.com, 59. finbold.com, 60. finbold.com, 61. economictimes.indiatimes.com, 62. economictimes.indiatimes.com, 63. ts2.tech, 64. nvidianews.nvidia.com, 65. nvidianews.nvidia.com, 66. ts2.tech, 67. nvidianews.nvidia.com, 68. nvidianews.nvidia.com, 69. www.ainvest.com, 70. ts2.tech, 71. ts2.tech, 72. www.marketbeat.com, 73. www.marketbeat.com, 74. www.fastcompany.com, 75. www.fastcompany.com, 76. nvidianews.nvidia.com, 77. finbold.com

Stock Market Today

  • MVV Energie Valuation After 4% Three-Month Rise: P/E Undervalued Yet DCF Fair Value Points to Overvaluation
    November 1, 2025, 9:44 PM EDT. MVV Energie has edged higher, up about 4% over three months, with the stock trading around €31.1 and a 5.7% one-year TSR. The stock shows a P/E of 13.4x, which traders may view as undervalued versus German and global utilities peers. However, a separate DCF analysis from Simply Wall St trims MVV's implied fair value to about €0.61, implying the shares could be overvalued at current levels if long-term cash flows don't accelerate. The contrast highlights a key debate: price momentum vs. earnings growth. If revenue momentum stalls, upside could fade despite the modest P/E discount. Investors should weigh the risk to growth against the apparent valuation gap and consider sensitivity to discount rate and cash flow assumptions.
  • (XAW:CA) Stock Analysis and AI Signals - iShares Core MSCI All Country World ex Canada ETF (XAW:CA) | November 2025
    November 1, 2025, 9:42 PM EDT. November 1, 2025 AI-generated signals for XAW:CA (iShares Core MSCI All Country World ex Canada) indicate a long-side plan with an entry near 47.82 and a stop loss at 47.58. No short positions are offered at this time. The update includes Ratings for Near, Mid, and Long terms, showing a mix of Strong and Weak signals. Traders should review the timestamp (Nov 1, 2025, 08:59 PM ET) and the accompanying chart for XAW:CA to gauge current momentum. As AI-generated signals are refreshed, stay tuned for any changes to risk levels or targets.
  • Oculis Holding (OCS): Is the Premium P/B Ratio Justified After Recent Share Gains?
    November 1, 2025, 9:12 PM EDT. Oculis Holding (OCS) has gained about 11% in the last month and ~14% year-to-date, reinforcing a momentum story that investors are watching. The stock trades at a price-to-book ratio (P/B) of 5.7x, well above the US pharma average and peers, suggesting the valuation is pricing in substantial future growth. Yet OCS is still unprofitable and not yet generating meaningful revenue milestones, making a high P/B potentially difficult to justify. If growth milestones or profitability don't materialize, the premium could be at risk. The market seems to have priced in upside, leaving little margin for error. Investors should weigh the momentum against the core risks-slower revenue growth and continued losses-before assuming more upside, and consider how a potential re-rating might occur once profitability or revenue milestones are achieved.
  • XMU:CA Stock Analysis - AI-Generated Signals, Trading Plans for iShares MSCI Min Vol USA ETF
    November 1, 2025, 8:24 PM EDT. Updated AI-Generated Signals for XMU:CA (iShares MSCI Min Vol USA Index ETF) highlight near-term sentiment and defined trades. The plan shows a Long setup: buy near 87.19 with a target of 90.50 and a stop loss at 86.75; a Short setup near 90.50 with a target of 87.19 and a stop at 90.95. AI-generated signals and ratings for November 1 list Near-term as Strong, Mid-term as Weak, and Long-term as Strong. The report, updated Nov 1, 2025, emphasizes risk controls and time-stamped data to guide traders monitoring XMU:CA price action and volatility.
  • TGRO:CA Stock Analysis and Trading Signals - TD Growth ETF Portfolio
    November 1, 2025, 8:22 PM EDT. Market readers get a concise look at TGRO:CA (TD Growth ETF Portfolio) with a long-term trading plan. The report notes a suggested entry: Buy near 24.44 and a protective stop loss at 24.32, with no current short recommendations. It also mentions updated AI-Generated Signals for TGRO:CA and a snapshot of the latest ratings across Near, Mid, and Long horizons (Near: Strong, Mid: Weak, Long: Strong). The piece emphasizes checking the timestamp on the data and points to the AI-generated signals page for TD Growth ETF Portfolio. Chart context is provided for TGRO:CA.
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?
Previous Story

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Nasdaq Frenzy: Tech Titans’ AI-Fueled Surge Hits Records Ahead of Fed Cut & Earnings Bonanza
Next Story

Amazon & Apple Earnings Ignite Market Rally as Tech Stocks Soar (But Fed Jitters Linger)

Go toTop